Visceral leishmaniasis associated with ixekizumab therapy presenting as hemophagocytic lymphohistiocytosis
Medicina Clínica · 2026-10 · 107683
DOI: 10.1016/j.medcli.2026.107683 ↗Kurz gefasst
Leserbrief in der Zeitschrift Medicina Clínica, 2026-10. Verfasst von Ángela García-Oro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hospital General de Villarrobledo, Albacete, Spain. Electronic address: angelagarciaoro@hotmail.com. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Internal Medicine, Hospital General de Villarrobledo, Albacete, Spain. Electronic address: angelagarciaoro@hotmail.com.
- Department of Internal Medicine, Hospital Quironsalud Albacete, Albacete, Spain.
- Honorary Professor, Faculty of Medicine, University of Castilla-La Mancha, Albacete, Spain.
Zitieren
APA
García-Oro, Á., Puerta-García, A., & Solera, J. (2026). Visceral leishmaniasis associated with ixekizumab therapy presenting as hemophagocytic lymphohistiocytosis. Medicina Clínica, 107683. https://doi.org/10.1016/j.medcli.2026.107683
Vancouver
García-Oro Á, Puerta-García A, Solera J. Visceral leishmaniasis associated with ixekizumab therapy presenting as hemophagocytic lymphohistiocytosis. Medicina Clínica. 2026:107683. doi:10.1016/j.medcli.2026.107683
BibTeX
@article{GarcaOro2026,
author = {García-Oro, Ángela and Puerta-García, Amparo and Solera, Javier},
title = {Visceral leishmaniasis associated with ixekizumab therapy presenting as hemophagocytic lymphohistiocytosis},
journal = {Medicina Clínica},
year = {2026},
pages = {107683},
doi = {10.1016/j.medcli.2026.107683}
}
EUVIMED